PF-AtlasClinical Trials › NCT01018303

Safety and Efficacy of an Antioxidant-rich Multivitamin Supplement in Cystic Fibrosis

AquADEK · Phase 1

Registry ID
NCT01018303
Phase
Phase 1
Status
Completed
Drug / intervention
AquADEK
Sponsor
University of Colorado, Denver
Start
2007-08
Enrollment
17
Locations
1

About this trial

The purpose of this study is to test the safety and efficacy of the final commercial formulation of an antioxidant enriched multivitamin supplement in softgel capsule form (AquADEKs) in increasing the plasma levels of certain nutrients and antioxidants in individuals with cystic fibrosis. Hypothesis: An oral antioxidant-rich multivitamin supplement (AquADEKs), which uses a Generally Regarded As Safe (GRAS) molecule to form micelle-like vehicles, will safely increase systemic levels of beta-carotene, coenzyme Q10, and gamma-tocopherol, decrease PIVKA-II levels, while maintaining levels of vitamins A and D in the normal range in persons with CF \> 10 years of age.

View NCT01018303 on ClinicalTrials.gov →

Explore related

Medical disclaimer. This page summarizes public trial data for NCT01018303 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.